BioCentury
ARTICLE | Company News

FDA approves AZ's hairy cell leukemia drug

September 13, 2018 9:02 PM UTC

FDA approved Lumoxiti moxetumomab pasudotox-tdfk from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat relapsed or refractory hairy cell leukemia in adults who have received at least two prior systemic therapies, including a purine nucleoside analog.

Lumoxiti, an anti-CD22 antibody variable fragment fused to the PE38 immunotoxin, has Orphan Drug status from FDA...

BCIQ Company Profiles

AstraZeneca plc

BCIQ Target Profiles

CD22